159 related articles for article (PubMed ID: 15168589)
1. Second malignant neoplasms following hematopoietic stem cell transplantation.
Friedman DL; Leisenring W; Schwartz JL; Deeg HJ
Int J Hematol; 2004 Apr; 79(3):229-34. PubMed ID: 15168589
[TBL] [Abstract][Full Text] [Related]
2. Secondary malignancies after hematopoietic stem cell transplantation.
Roziakova L; Bojtarova E; Mistrik M; Mladosievicova B
Neoplasma; 2011; 58(1):1-8. PubMed ID: 21067259
[TBL] [Abstract][Full Text] [Related]
3. The risk of malignancies in patients receiving hematopoietic stem cell transplantation: a systematic review and meta-analysis.
Heydari K; Shamshirian A; Lotfi-Foroushani P; Aref A; Hedayatizadeh-Omran A; Ahmadi M; Janbabei G; Keyhanian S; Zaboli E; Ghasemzadeh SM; Alizadeh-Navaei R
Clin Transl Oncol; 2020 Oct; 22(10):1825-1837. PubMed ID: 32108275
[TBL] [Abstract][Full Text] [Related]
4. Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma.
Tward J; Glenn M; Pulsipher M; Barnette P; Gaffney D
Leuk Lymphoma; 2007 Aug; 48(8):1482-95. PubMed ID: 17701578
[TBL] [Abstract][Full Text] [Related]
5. Second malignancies after allogeneic hematopoietic stem cell transplantation: new insight and current problems.
Adès L; Guardiola P; Sociè G
Blood Rev; 2002 Jun; 16(2):135-46. PubMed ID: 12127957
[TBL] [Abstract][Full Text] [Related]
6. Late complications in blood and marrow transplant survivors.
Majhail NS
Minn Med; 2010 Oct; 93(10):45-9. PubMed ID: 21140762
[TBL] [Abstract][Full Text] [Related]
7. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.
Forrest DL; Hogge DE; Nevill TJ; Nantel SH; Barnett MJ; Shepherd JD; Sutherland HJ; Toze CL; Smith CA; Lavoie JC; Song KW; Voss NJ; Gascoyne RD; Connors JM
J Clin Oncol; 2005 Nov; 23(31):7994-8002. PubMed ID: 16204014
[TBL] [Abstract][Full Text] [Related]
8. Risk of secondary solid malignancies after allogeneic hematopoietic stem cell transplantation and preventive strategies.
Adhikari J; Sharma P; Bhatt VR
Future Oncol; 2015; 11(23):3175-85. PubMed ID: 26551415
[TBL] [Abstract][Full Text] [Related]
9. Secondary Neoplasms of the Female Lower Genital Tract After Hematopoietic Cell Transplantation.
Chang HA; Armenian SH; Dellinger TH
J Natl Compr Canc Netw; 2018 Feb; 16(2):211-218. PubMed ID: 29439180
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk factors of secondary cancers after allogeneic stem cell transplantation: analysis of a single centre cohort with a long follow-up.
Martelin E; Volin L; Itälä-Remes M; Niittyvuopio R; Lindström V; Heiskanen J; Ruutu T; Nihtinen A
Bone Marrow Transplant; 2019 Feb; 54(2):334-337. PubMed ID: 30104720
[No Abstract] [Full Text] [Related]
11. Second Malignancies after Hematopoietic Stem Cell Transplantation.
Danylesko I; Shimoni A
Curr Treat Options Oncol; 2018 Feb; 19(2):9. PubMed ID: 29423555
[TBL] [Abstract][Full Text] [Related]
12. Second malignancies after allogeneic hematopoietic cell transplantation.
Lowe T; Bhatia S; Somlo G
Biol Blood Marrow Transplant; 2007 Oct; 13(10):1121-34. PubMed ID: 17889348
[TBL] [Abstract][Full Text] [Related]
13. Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study.
Cohen A; Rovelli A; Merlo DF; van Lint MT; Lanino E; Bresters D; Ceppi M; Bocchini V; Tichelli A; Socié G
J Clin Oncol; 2007 Jun; 25(17):2449-54. PubMed ID: 17557958
[TBL] [Abstract][Full Text] [Related]
14. Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis.
Forrest DL; Nevill TJ; Naiman SC; Le A; Brockington DA; Barnett MJ; Lavoie JC; Nantel SH; Song KW; Shepherd JD; Sutherland HJ; Toze CL; Davis JH; Hogge DE
Bone Marrow Transplant; 2003 Nov; 32(9):915-23. PubMed ID: 14561993
[TBL] [Abstract][Full Text] [Related]
15. Incidence and Risk Factors for De Novo Cutaneous Squamous Cell Carcinoma in a Contemporary Cohort of Long-Term Hematopoietic Cell Transplantation Survivors.
Berano Teh J; Abdulla F; Peng K; Atencio L; Echevarria M; Iukuridze A; Geller AC; Wong FL; Forman SJ; Nakamura R; Modi B; Armenian SH
J Invest Dermatol; 2021 Aug; 141(8):2073-2076.e5. PubMed ID: 33609555
[No Abstract] [Full Text] [Related]
16. High incidence of oral squamous cell carcinoma independent of HPV infection after allogeneic hematopoietic SCT in Taiwan.
Chen MH; Chang PM; Li WY; Hsiao LT; Hong YC; Liu CY; Gau JP; Liu JH; Chen PM; Chiou TJ; Tzeng CH
Bone Marrow Transplant; 2011 Apr; 46(4):567-72. PubMed ID: 20622906
[TBL] [Abstract][Full Text] [Related]
17. Second malignancies after allogeneic stem cell transplantation with reduced-intensity conditioning: is the incidence reduced?
Shimoni A
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1669-70. PubMed ID: 25223487
[No Abstract] [Full Text] [Related]
18. Approaches to reduce the long-term burden of treatment-related complications in survivors of childhood cancer.
Armenian SH; Kremer LC; Sklar C
Am Soc Clin Oncol Educ Book; 2015; ():196-204. PubMed ID: 25993157
[TBL] [Abstract][Full Text] [Related]
19. The risk of secondary leukemias following autologous stem cell transplantation.
Bishop MR
Leuk Res; 1999 Mar; 23(3):281-2. PubMed ID: 10071082
[No Abstract] [Full Text] [Related]
20. Mucosal melanoma following autologous stem cell transplantation for non-Hodgkin's lymphoma (NHL).
Ben-Yosef R; Braverman I; Saah D; Nagler R; Shohat S; Or R; Nagler A
Bone Marrow Transplant; 1996 Nov; 18(5):1017-9. PubMed ID: 8932860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
